menu search

Outlook Therapeutics® Requests Type A Meeting With FDA

Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss […] The post Outlook Therapeutics® Requests Type A Meeting With FDA appeared first on ForexTV... Read More
Posted: Sep 29 2023, 12:05
Author Name: forextv
Views: 102062

Search within

Pages Search Results: